GENFIT Share Price Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 89.63M 95.84M 7.67B | Sales 2025 * | 48.78M 52.16M 4.18B | Capitalization | 160M 171M 13.66B |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.04M 1.28B | Net income 2025 * | -21M -22.45M -1.8B | EV / Sales 2024 * | 1.47 x |
Net cash position 2024 * | 27.6M 29.51M 2.36B | Net cash position 2025 * | 44.9M 48.01M 3.84B | EV / Sales 2025 * | 2.35 x |
P/E ratio 2024 * |
6.83
x | P/E ratio 2025 * |
24.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.77% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 30/04/18 |
Founder | 68 | 31/08/99 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 03/03/21 | |
Founder | 68 | 31/08/99 | |
Founder | 52 | 14/09/99 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |